Want to see PBH full AI Analyst Report?
PBH Stock Chart & Stats
$58.13
-$0.15(-0.20%)
At close: 4:00 PM EST
$58.13
-$0.15(-0.20%)
Day’s Range― - ―
52-Week Range$42.62 - $80.69
Previous CloseN/A
Volume57.25K
Average Volume (3M)783.95K
Market Cap
$2.34B
Enterprise Value$3.17B
Total Cash (Recent Filing)$63.87M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)12.5
Beta0.32
Next Earnings
Jul 30, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.94
Shares Outstanding47,372,166
10 Day Avg. Volume630,153
30 Day Avg. Volume783,950
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.30
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda9.57
Forecast
1Y Price Target
$72.00Price Target Upside23.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)4.54
Revenue Forecast (FY)$1.19B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent operating cash flow (~$230M–$260M historically) and FCF that closely tracks earnings provide durable internal funding for acquisitions, buybacks, deleveraging and reinvestment. Reliable cash conversion improves strategic optionality and reduces reliance on external financing over the medium term.
Margin ResilienceSustained mid‑50% gross margins and high‑teens net margins through recent volatility indicate a structurally profitable product mix and pricing power in OTC categories. Low capital intensity (capex ~1%–3% of sales) further supports margin sustainability and cash conversion across cycles.
Scale Via Acquisitions & BrandsTargeted M&A (Breathe Right, LaCorium, Pillar5, Pillar5 investment) expands category exposure, adds leading franchises and manufacturing capability, and materially enlarges revenue base. Combined with a growing e‑commerce channel (~18%), the strategy diversifies go‑to‑market and supports medium‑term revenue and margin accretion.
Bears Say
Top‑line WeaknessRecurring flat to declining organic revenue and a fiscal '26 revenue decline highlight limited underlying category growth and exposure to timing/operational hits. This reduces operating leverage and means the company must rely on acquisitions or sustained execution improvements to restore multi‑year organic growth.
Operational Supply RiskMaterial supply disruptions (Clear Eyes) and Pillar5 ramp uncertainty created quarter‑to‑quarter volatility in shipments and revenues. Until internal manufacturing and logistics stabilize, operational execution remains a structural risk that can mute recoveries and constrain reliable growth and margin improvement.
Higher Near‑term Leverage & Covenant RiskLarge cash M&A funded with a substantial term loan pushes near‑term leverage materially higher (~4x pro forma). Management plans deleveraging but until achieved the company faces increased interest, covenant constraints and reduced financial flexibility, particularly if cash flow underperforms due to operational issues.
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $42.62 and its highest was $80.69 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.34B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Jul 30, 2026 which is in 26 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on May 13, 2026. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by -$0.16.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 0.88.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,372,166 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.23 in its last earnings report, missing expectations of $1.39. Following the earnings report the stock price went down -11.349%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.00 (23.86% Upside)
$72.00 (23.86% Upside)
Blogger Sentiment
Neutral
PBH Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 815.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $225.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.42%
12-Months-Change
Fundamentals
Return on Equity
10.29%
Trailing 12-Months
Asset Growth
2.66%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBH Company Deck
PBH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: the call highlighted strong cash generation, margin resilience, strategic M&A (Pillar5, Breathe Right, LaCorium) and digital/channel strengths (e‑commerce ~18%), which position the company for medium‑term upside. However, significant near‑term execution risks—chiefly Clear Eyes supply disruptions, production ramp uncertainty, and shipping disruptions from geopolitical events—drove fiscal '26 revenue declines and create short‑term volatility. Management provided cautious fiscal '27 guidance that assumes improvement in the back half of the year and emphasized deleveraging after acquisitions.View all PBH earnings summariesPBH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$72.00
▲(23.86% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.41% Insiders
46.33% Mutual Funds
0.53% Other Institutional Investors
21.88% Public Companies and
Individual Investors









